Skip to content

Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin

Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02127736
Enrollment
Unknown
Registered
2014-05-01
Start date
Unknown
Completion date
2014-09-30
Last updated
2014-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Participants

Brief summary

The purpose of this study is to evaluate whether an Amitriptylin induced change in sleep patterns can be conditioned according to learning theory in healthy participants.

Interventions

DRUGAmitriptyline
DRUGPlacebo

Sponsors

Winfried Rief
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years

Inclusion criteria

* age between 18 years to 69 years * willingness to refrain from alcohol consumption throughout the study * regular sleeping habits * fluent in German language * is not dependent on driving to get to the study center * provide written informed consent * ability to understand the explanations and instructions given by the study physician and the investigator

Exclusion criteria

* Contraindications to study medication intake according to the information sheet for health professionals (Summary of medicinal Product Characteristics, SmPC) assessed by physical examination (including ECG) and medical history * allergies to amitriptyline hydrochloride or any of its ingredients * acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic drug * urinary retention * delirium * untreated closed-angle glaucoma * prostatic hyperplasia * pyloric stenosis * paralytic ileus * suicidal thoughts * liver/ kidney/ pulmonary insufficiency * myasthenia gravis * hypokalemia * bradycardia * coronary heart disease, cardiac arrhythmias, long QT syndrome or other clinically relevant cardiac disorders * increased risk of seizures/ history of seizures * substance dependence syndrome/ history of substance dependence syndrome * Allergies to ingredients of placebo or novel-tasting drink (CS) * currently pregnant (verified by urine pregnancy test) or lactating * patients suffering from a mental disorder as verified by the International Diagnosis Checklists (IDCL) * patients suffering from a medical condition (assessed by the study physician) * Concomitant medication interfering with study medication intake due to potential interactions * participation in any other clinical trial 3 months prior to visit 1 * employee of the Sponsor or the principal investigator

Design outcomes

Primary

MeasureTime frameDescription
Objective Total Sleep Time5 nights during the studyassessed by polysomnography
Percentage of rapid eye movement (REM) sleep5 nights during the studyassessed by polysomnography

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026